AN2 Therapeutics, Inc.
ANTX
$1.10
-$0.03-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.85M | 3.21M | 3.48M | 3.73M | 3.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.54M | 8.61M | 11.77M | 15.88M | 18.30M |
| Operating Income | -11.54M | -8.61M | -11.77M | -15.88M | -18.30M |
| Income Before Tax | -10.65M | -7.52M | -12.75M | -14.44M | -16.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.65M | -7.52M | -12.75M | -14.44M | -16.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.65M | -7.52M | -12.75M | -14.44M | -16.62M |
| EBIT | -11.54M | -8.61M | -11.77M | -15.88M | -18.30M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.35 | -0.25 | -0.43 | -0.48 | -0.56 |
| Normalized Basic EPS | -0.22 | -0.16 | -0.22 | -0.30 | -0.35 |
| EPS Diluted | -0.35 | -0.25 | -0.43 | -0.48 | -0.56 |
| Normalized Diluted EPS | -0.22 | -0.16 | -0.22 | -0.30 | -0.35 |
| Average Basic Shares Outstanding | 30.05M | 29.88M | 29.84M | 29.82M | 29.76M |
| Average Diluted Shares Outstanding | 30.05M | 29.88M | 29.84M | 29.82M | 29.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |